Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D058070 | Asymptomatic Diseases NIH | 0.41 |
| D007239 | Infection NIH | 0.03 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 2 clinical trials
Coronavirus disease 2019 (Covid-19) has been declared global emergency with immediate safety, preventative and curative measures to control the spread of virus. Confirmed cases are treated with clinical management as they are diagnosed but so far, there is no effective treatment or vaccine yet for Covid-19. With recommended guidelines of AYUSH Ministry, India, the use of Ayurveda for Covid-19 has increased; however, its efficacy and safety in Covid-19 confirmed patients remain unclear. Present study examined the efficacy and safety of one of the recommended Ayurveda drug (Guduchi Ghan Vati) compared with standard care for patients with asymptomatic Covid-19 patients.
Description: Virologic clearance indicates the duration from the first Covid-19 positive result to the first Covid-19 negative result
Measure: Virologic clearance Time: 21 daysDescription: change in the number of patients going from asymptomatic to moderately disease
Measure: Change in the number of patients going from asymptomatic to moderately disease Time: 10-days of hospital admissionDescription: Total duration of stay in hospital for complete recovery
Measure: Hospital Stay Time: 21 daysDescription: Clinically relevant adverse effects of Guduchi Ghan Vati (Disability, Discomfort reported)
Measure: Clinically relevant adverse effects Time: 21-daysThe emergence of asymptomatic patients poses a significant challenge to the prevention and treatment of the epidemic.There have not been any treatment options that reduce the viral load or preventive options that reduce the risk of developing severe conditions.Therefore, present feasibility study of the safety and efficacy of Guduchi Ghan Vati was conducted in asymptomatic patients with COVID-19
Description: Virologic clearance indicates the duration from the first Covid-19 positive result to the first Covid-19 negative result
Measure: Virologic clearance Time: 14 daysDescription: Total duration of stay in hospital for complete recovery
Measure: Hospital Stay Time: 14 daysDescription: Clinically relevant adverse effects of Guduchi Ghan Vati were reported using Adverse Drug Reaction reporting form
Measure: Clinically relevant adverse effects Time: 14 daysDescription: Routine blood tests were performed to assess complete blood counts, blood biochemistry parameters {Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), Urea, C-reactive protein (CRP), as well as Albumin} and immunoglobulines.
Measure: Laboratory tests Time: change from baseline to 14 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports